In this overview, we present what was new in the field of haematopoietic cell transplantation (HCT) at ASH 2022. Key messages were that all AML patients – even those without complete remission – are eligible for HCT and that there is a donor for (virtually) everybody thanks to the use of post-transplant cytarabine and abatercept. Furthermore, first-line acute graft-versus-host disease treatment in standard risk patients is feasible without corticosteroids or with low-dose corticosteroids. Finally, it was reported that a non-restrictive diet does not increase infections in patients with neutropenia after stem cell transplantation.
(BELG J HEMATOL 2023;14(1):26–9)